

Extension of Share Purchase Plan Closing Date and Updates to Timetable for the Offers

Memphasys Limited (ASX: MEM) (**Memphasys** or **Company**) refers to its prospectus dated 20 September 2024, as supplemented by the supplementary prospectus dated 8 October 2024 (together, **Prospectus**). Unless otherwise stated in this release, defined terms have the same meaning as in the Prospectus.

The Board of Memphasys have agreed to extend the closing date of the SPP Offer under the Prospectus from 5:00pm (AEDT) on 24 October 2024, to **5:00pm (AEDT) on Thursday, 31 October 2024**.

Feedback from our shareholder consultation process has indicated shareholders require additional time to review the Company's current operations and complete the SPP Offer, so the Company has agreed to extend the Closing Date by one week.

The issue of Shares and Attaching Options under the Prospectus Offers (being the SPP Offer, Placement Offer and Top Up Offer) remains conditional upon receipt of Shareholder approval at the General Meeting to be held on 25 October 2024.

The issue price of Shares to be issued under the SPP Offer and the Placement Offer remains the lower of \$0.008 per Share and a 20% discount to the 5-day VWAP as at the date of issue of the Shares under the respective offers. It is still the Company's intention that the Shares under the SPP Offer and Placement Offer will be issued on the same date and will therefore have the same issue price. As such, the closing dates and settlement dates for the Placement Offer and Top Up Offer have also been extended.

The revised timetable for the Offers is as follows (items in bold text have been updated from the original dates disclosed in the Prospectus):

ACTION	DATE*
Record Date for SPP Offer	11 September 2024
Announcement of SPP, Placement and Top Up Offer and lodgement of Appendix 3B with ASX (prior to commencement of trading)	12 September 2024
Release of updated Appendix 3B and lodgement of Prospectus with ASIC and ASX	20 September 2024
Opening date of the Offers under the Prospectus	25 September 2024
Date of General Meeting	25 October 2024
Closing Date of the SPP Offer and the Placement Offer	5:00pm (AEDT) on Thursday, 31 October 2024
Announce results of SPP Offer Issue of Shares under SPP Offer and Placement Offer and Attaching Options and lodgement of Appendix 2A with ASX applying for quotation of Shares issued under SPP Offer and Placement Offer	5 November 2024



Quotation on ASX of Shares issued under SPP Offer and Placement Offer	6 November 2024
Closing Date for Top Up Offer**	<i>on or before 13 December 2024</i>
Issue of Shares under Top Up Offer and Attaching Options and lodgement of Appendix 2A with ASX applying for quotation of Shares issued under Top Up Offer**	+3 Business Days after closing date of top up offer - 19 December 2024
Quotation on ASX of Shares issued under Top Up Offer**	+4 Business Days after closing date of top up offer – 20 December November 2024

* The above dates are indicative only and may change without prior notice.

** It is the Company's present intention to proceed with the Top Up Offer to the full extent of investor demand and subject to the allocation policy disclosed in the Prospectus.

The Offers are seeking to raise up to \$3 million for:

- Finalisation of Felix™ clinical trial, a milestone for advancing strategic investor interest and expedited distributor sales in Japan;
- Progressing an equine fertility study, where commercial sales are expected within 12 months; and
- Conducting a study to establish a baseline and thresholds for oxidative stress likely to be associated with meaningful events in reproductive performance.

Further details are outlined in the Prospectus, and which should be read in full before determining whether to subscribe for Shares under the SPP Offer.

This announcement has been approved for release by the board of Memphasys Limited.

ENDS

For further information, please contact:

Dr David Ali
Managing Director / Chief Executive Officer
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

Andrew Metcalfe
Company Secretary
Memphasys Limited
Tel: +61 412 125 090
E: andrew@accosec.com

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's patented bioseparation technology, utilised by the Company's most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.